Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro's dose has to increase over time because the starting dose of 2.5 mg is designed to let your body adjust, not to produce significant weight loss. Titration (the process of stepping up through 5 mg, 7.5 mg, 10 mg, 12.5 mg and finally 15 mg) gradually brings tirzepatide to the level where it has its full effect on appetite and blood-sugar regulation. The schedule is built into the licensed treatment: a prescriber guides every step, and the NHS tirzepatide medicines page outlines why clinical oversight matters throughout. Mounjaro is a prescription-only medicine; a clinician assesses suitability before any dose can be issued or changed.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The tirzepatide molecule is powerful. Giving a full therapeutic dose on day one would cause most people significant gastrointestinal distress (nausea, vomiting, loose stools) that would make continuing treatment very difficult. So the 2.5 mg pen comes first. It introduces the mechanism gently: your gut slows its emptying rate, your appetite signals start to shift, and your body has roughly four weeks to adapt before anything changes.
Think of it less as a treatment phase and more as an acclimatisation period. Most people notice relatively modest changes in appetite at 2.5 mg. That is expected. The dose was never meant to carry the therapeutic load, it was meant to make the next step tolerable.
This is one of the most common points of confusion our prescribers hear about: patients stopping early because they feel the medicine "isn't working" at the starter dose. Staying the course through the titration schedule is part of how the treatment is designed to succeed. If you have questions about the pace of titration, the Mounjaro treatment overview has further background.
After the initial four weeks, the licensed schedule moves to 5 mg, then 7.5 mg, and so on, with each step separated by roughly four weeks at the current dose. The reason each step takes a month is the same as the reason titration exists at all: the body needs time to recalibrate. GIP and GLP-1 receptor activation changes gastric emptying speed, modifies hunger hormones, and alters how the brain registers fullness. Those adjustments are not instantaneous.
At each new dose, side effects tend to peak in the first week or two and then settle. A practical habit worth building: in the week after stepping up, keep a brief note on your phone about how you are feeling, just appetite level, energy and any nausea. It takes under a minute and gives your prescriber genuinely useful information at your next review rather than a general impression.
If you are wondering whether you actually have to increase your Mounjaro dose, the short answer is that it is a clinical decision, not automatic. The 5 mg dose page also covers what to expect at that particular step.
The target is the highest dose your body can tolerate well. For most people following the full schedule, that is 15 mg. For some, it is 10 mg or 12.5 mg, and that is not a failure of the treatment or the patient; it reflects normal physiological variation.
NICE's appraisal of tirzepatide, TA1026, describes the clinical expectation in terms of "highest tolerated dose" rather than insisting on 15 mg universally. The trial data from SURMOUNT-1 showed average body-weight reductions of around 20–21% at 15 mg over 72 weeks, figures achieved because participants reached and stayed at their maintenance dose, not because they rushed through titration. Weight loss tends to continue for months after reaching a stable dose, which is why the reasoning behind increasing your Mounjaro dose is really two questions: why titrate at all, and why not stop titrating early. Both answers point to the same place, the medicine's effect accumulates at the dose level where the receptors are adequately engaged.
For a broader look at how treatment costs vary across the dose schedule, the context around Mounjaro pricing in the UK is worth reading alongside your prescriber's guidance.
Titration is not a rigid conveyor belt. If nausea, vomiting or other gastrointestinal symptoms are significant at a given dose, a prescriber will typically recommend staying at that step for another four weeks (or occasionally longer) before moving up. This is clinically normal and is built into how the medicine is meant to be used. Rushing to increase the Mounjaro dose when side effects are poorly controlled does not help weight loss and makes stopping treatment more likely.
Side effects to keep a close eye on beyond typical GI symptoms include severe, persistent stomach pain that radiates to the back. That warrants urgent medical attention. For a full picture of the side-effect profile and when to seek help, the treatment FAQs cover the common questions, and the NHS medicines page is always the right first reference for anything clinical. If something feels wrong between reviews, our aftercare team is available seven days a week.
If you are ready to discuss where you are in the titration process, or to begin treatment, check your eligibility with a free consultation, a real prescriber reviews your answers the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.